New non-opioid treatment for chronic pain using spinal delivery
Novel, Non-Opioid, Non-Addictive Intrathecal Therapy for the Treatment of Chronic Pain
This study is testing a new way to help people with chronic pain by using a special medication delivered directly to the spinal cord, which could be a safer option than traditional painkillers for those who haven't found relief with other treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Centrexion Therapeutics Corporation NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10795789 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating chronic pain through the use of a non-opioid medication delivered directly to the spinal cord via an implantable pump. The therapy aims to provide effective pain relief while minimizing the risks associated with traditional opioid medications. By focusing on a specific receptor in the nervous system, this treatment could offer a safer alternative for patients who have not responded to other pain management strategies. The study will include early-phase clinical trials to evaluate the safety and efficacy of this new therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with severe chronic pain who have not found relief from existing treatments and are seeking alternatives to opioids.
Not a fit: Patients who are not experiencing chronic pain or those who have not exhausted other pain management options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer, effective alternative to opioids for patients suffering from chronic pain.
How similar studies have performed: Previous research has shown promise in using targeted spinal delivery methods for pain management, but this specific approach with the NOPr agonist is novel.
Where this research is happening
Boston, United States
- Centrexion Therapeutics Corporation — Boston, United States (Active)
Researchers
- Principal investigator: Campbell, James N — Centrexion Therapeutics Corporation
- Study coordinator: Campbell, James N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.